Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering suffers delay on Zevalin EU launch

This article was originally published in Clinica

Executive Summary

German company Schering is to delay the launch of its radioimmunotherapy product Zevalin (90Y-ibritumomab tiuxetan) in the EU because of certain technical compliance issues. The Berlin-based company, which had planned to launch the product in the second half of 2002, says it is examining all options to release the product as quickly as possible - hopefully in the second half of 2003. Zevalin is the first radioimmunotherapy treatment for certain Non-Hodgkins Lymphoma. Schering stressed that the clinical efficacy of the product was not in question.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel